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Background: The Control of Allergic Rhinitis and Asthma Test (CARAT10) has been proposed as the first tool to
implement the Allergic Rhinitis and its Impact on Asthma initiative guidelines in clinical practice. To serve this
purpose, it must have adequate properties to assess the control of an individual over time. This study aimed to
prospectively assess the test-retest reliability, responsiveness and longitudinal validity of CARAT10.
Methods: Adults with asthma and allergic rhinitis were enrolled at 4 outpatient clinics of Portuguese central
hospitals. At each of the two visits, 4 to 6 weeks apart, patients filled out CARAT10 and additional questionnaires,
followed by a medical evaluation blinded to the questionnaires’ answers.
Results: From the 62 patients included, 51 patients completely filled out CARAT10 at both visits. The test-retest
reliability, computed as an intra-class correlation coefficient, was 0.82. Regarding responsiveness, a significant
change (p = 0.002) of CARAT10 score in clinically unstable patients was observed (95%CI -5.08; -1.31) and the
Guyatt’s responsiveness index was 1.54. As for the longitudinal validity assessment, the correlation coefficients of
the changes of CARAT10 scores with those of ACQ5 and symptoms VAS ranged from 0.49 to 0.65, while with the
physician assessment of control they ranged from 0.31 to 0.41.
Conclusion: CARAT10 has good test-retest reliability, responsiveness and longitudinal validity. It can be used to
assess control of allergic rhinitis and asthma, both to compare groups in clinical studies and to evaluate individual
patients in clinical practice.
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Rhinitis and asthma are highly prevalent diseases that
are closely associated. A few questionnaires have been
developed and validated to assess the control of rhinitis
[1,2] and asthma [3,4]. For over a decade, the Allergic
Rhinitis and its Impact on Asthma (ARIA) initiative has
recommended the simultaneous assessment and mana-
gement of these diseases [5,6]. Recent observational stu-
dies reinforced the association of rhinitis and asthma. In* Correspondence: fonseca.ja@gmail.com
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reproduction in any medium, provided the ora cross-sectional study of asthma patients from 85 primary
care practices in the United Kingdom, self-reported rhi-
nitis was identified as a major predictor of poor asthma
control [7]. Also, data from the West Sweden Asthma
Study linked the degree of rhinitis with the risk of having
multi-symptom asthma [8].
We have previously developed the Control of Aller-
gic Rhinitis and Asthma Test – a 17-item version [9] –
employing a formal methodological approach to ensure its
quality and content validity [10]. Subsequently, we con-
ducted a cross-sectional study, in which we performed
factor analysis to reduce the questionnaire and assess its
unidimensionality, resulting in a simple 10-item version
(CARAT10) [11]. In that study, we described how 2l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 – Sample’s characteristics and results of
physician assessment, control questionnaires and lung
function tests
1st visit n = 62 2nd visit n = 61
Gender Female n (%) 37 (60) 36 (59)
Age mean (SD) years 39.6 (14.5) 39.8 (14.5)
Physician assessment n (%)
Asthma severity
Intermittent 12 (19) 7 (12)
Mild persistent 21 (34) 16 (28)
Moderate persistent 24 (39) 27 (48)
Severe persistent 5 (8) 7 (12)
Rhinitis classification
Intermittent 15 (28) 16 (34)
Persistent 38 (72) 31 (66)
Mild 27 (51) 26 (58)
Moderate/severe 26 (49) 19 (42)
Control
Both controlled 24 (39) 33 (59)
Only asthma controlled 15 (24) 8 (14)
Only rhinitis controlled 8 (13) 6 (11)
Both uncontrolled 15 (24) 9 (16)
Treatment decision
Reduce 3 (5) 2 (4)
Maintain 29 (47) 42 (75)
Increase 30 (48) 12 (21)
ACQ5 score median (P25-P75) 1 (0.2-2.5) 0.8 (0-2.2)
<0.5 n (%) 22 (35) 26 (42)
0.5–1.5 n (%) 14 (23) 12 (20)
>1.5 n (%) 26 (42) 23 (38)
VAS* median (P25-P75)
All symptoms 5 (2-7) 4 (2-6.5)
Bronchial/pulmonary symptoms 4 (2-7) 3 (2-6)
Nasal symptoms 5.7 (3-8) 3 (2-7)
Lung function mean (sd)#
FVC 102 (17.1) 100 (20.8)
FEV1 92 (19.7) 90 (23)
PEF 89 (25) 88 (26.7)
FENO50
§ 30 (23.1) 24 (21.7)
ACQ5 – Asthma control questionnaire (5-question); VAS – visual analogue
scale; FVC – forced vital capacity; FEV1 – forced expiratory volume in 1 second;
PEF – peak expiratory flow; FENO50- fractional exhaled nitric oxide.
*1-10, 1 being no disturbance; # 1st visit n = 55; 2nd visit n = 53; § 1st visit
n = 23; 2nd visit n = 31.
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version, matching the initial theoretical subdomains of
asthma and allergic rhinitis. Nevertheless, we demons-
trated that CARAT10 has good internal consistency, simi-
lar to that of widely used asthma control questionnaires,
thus supporting the concept of assessing allergic rhinitis
and asthma simultaneously (construct/structural validity).
Finally, we also showed that CARAT10 has good discri-
minative properties and concurrent validity [11].
CARAT10 has been proposed as the first tool to imple-
ment ARIA guidelines in clinical practice [12]. To serve
this purpose, such tool must have adequate properties to
assess asthma and allergic rhinitis control of an individual
over time.
Thus, this study aimed to prospectively assess the test-
retest reliability, responsiveness and longitudinal validity
of CARAT10.
Methods
Study design and setting
This prospective observational study comprised two visits,
4 to 6 weeks apart, and was conducted in the first semes-
ter of 2009.
Patients were enrolled in 4 allergy outpatient clinics
of central hospitals in three Portuguese regions – north
(Porto and Gaia), south (Lisbon) and the Azores islands
(Ponta Delgada).
The study was approved by the Hospital S. João review
board (Comissão de Ética para a Saúde) and was given
the project nº 120/08. Each patient gave his/her written
informed consent.
Participants
All patients between 18 and 70 years of age, with a med-
ical diagnosis of asthma and allergic rhinitis and at least
6 months of follow-up at the clinic were eligible. Only
patients unable to fill the questionnaire were excluded.
Data collection
At each visit, patients were asked to fill CARAT10 and ad-
ditional tools: the Asthma Control Questionnaire (ACQ5)
[3] and three visual analogue scales (VAS) concerning all
airways symptoms, bronchial/pulmonary symptoms and
nasal symptoms as measures of self-perceived control.
They also underwent lung function tests followed by
a medical evaluation. The study design is described in the
Additional file 1: Figure S1.
Lung function and exhaled nitric oxide (FENO50) were
measured according to the 2005 ATS/ERS position state-
ments [13,14]. Lung function variables included the forced
vital capacity (FVC), the forced expiratory volume in 1 se-
cond (FEV1) and the peak expiratory flow (PEF). FENO50
was evaluated only in two of the four centres and ex-
pressed as parts per billion (ppb).The medical evaluation was carried out by the attend-
ing allergy specialist, who was blinded to the question-
naires’ answers. The physician classified the patient’s
rhinitis and asthma severity and rated the rhinitis and
Table 2 – Comparison of CARAT10 scores according to the patients’ self-perceived control
Controlled‡ Not controlled Total
mean (SD) [min-max] mean (SD) [min-max] mean (SD) [min-max]
1st visit CARAT10 * 22 (4.93) [11-29] 12.3 (5.91) [3-24] 18 (7) [3-29]
Rhinitis subscore # 7.5 (2.89) [2-11] 3.1 (2.57) [0-10] 5.2 (3.49) [0-11]
Asthma subscore § 14.9 (2.41) [9-18] 8.3 (4.87) [1-18] 12.7 (4.67) [1-18]
2nd visit CARAT10* 23.4 (5.12) [10-30] 14.8 (7.61) [4-27] 20.4 (7.32) [4-30]
Rhinitis subscore # 8.3 (2.64) [2-12] 4.5 (3.24) [1-11] 7.2 (3.33) [1-12]
Asthma subscore § 15 (3.13) [6-18] 8.8 (4.53) [3-17] 13.4 (4.48) [3-18]
‡ The classification of self-preceived control was established with the patients’ all symptoms VAS for CARAT10, with the nasal symptoms VAS for the rhinitis
subscore and with the bronchial/pulmonary symptoms VAS for the asthma subscore. * Range 0-30; # Range 0-12; § Range 0-18.
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judgment and bearing in mind the classifications of
ARIA [5] and Global Initiative for Asthma (GINA) [15].
The treatment decisions were made by the attending
physician, based on the clinical history, physical examina-
tion and lung function following ARIA and GINA guide-
lines. In addition, known allergies and current medication,Figure 1 CARAT10 and its subscores plotted against the classification
recommendations and GINA guidelines.as well as the decision regarding treatment plan (increase,
maintain or decrease treatment) were registered. In the
second visit, the same procedures were repeated and,
additionally, the physician filled out two 10 cm VAS
regarding the variation in asthma control and in rhinitis
control (from 0 - greatest worsening, to 10 - greatest
improvement).s of rhinitis severity and asthma control, according to ARIA
Table 3 – Spearman’s correlations of CARAT10 and its factors with external measures of rhinitis and asthma control in
the first visit
Symptoms VAS Physician assessment
ACQ5 All symptoms Bronchial/pulmonary symptoms Nasal symptoms Asthma control Rhinitis control
CARAT10 −0.79 −0.76 −0.75 −0.69 0.58 0.34*
Rhinitis subscore −0.50 −0.59 −0.51 −0.70 0.35* 0.43
Asthma subscore −0.78 −0.62 −0.71 −0.49 0.65 0.24#
The correlations between the measures of similar domains are shown in bold.
All correlations coefficients met the a priori predictions and were statistically significant with p < 0.001, except * p < 0.01 and # p = 0.073.
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The statistical analysis was carried out using SPSS 19.0
(SPSS Inc., Chicago, IL, USA). The level of significance
was set at p < 0.05. The population was described using
standard descriptive statistical techniques.
We derived dichotomous variables, classifying the pa-
tient as having controlled or not controlled asthma and
controlled or not controlled rhinitis, from the physician’s
control VAS. Patients were categorized as controlled if
the physician filled out the VAS in the ]6,10]cm interval.
Patients who were graded between 5.0 and 6.0 in the
second visit’s control variation VAS were considered to
be clinically stable [3].
We classified the patients’ rhinitis severity according
to the ARIA recommendations and the asthma control
according to the GINA guidelines. The results from both
visits were pooled and were plotted against the scores in
CARAT10 and its factors.Properties of CARAT10
The CARAT10 internal consistency analysis comprised the
assessment of its internal consistency with Cronbach’s α.
The test-retest reliability was assessed using intra-class
correlation coefficient (ICC) in clinically stable patients
between visits [16].
The concurrent validity was studied using Spearman’s
correlation coefficients between CARAT10/CARAT factors
and 1) control assessment instruments or 2) physician’s
assessment.
The responsiveness of CARAT10 was evaluated in the
group of clinically unstable patients – those with either
unstable asthma, unstable rhinitis, or both. We used aTable 4 – Longitudinal validity – comparison of the variation
control
Symptoms VA
ΔACQ5 ΔAll symptoms ΔBronchial/pulmonary s
ΔCARAT10 −0.63 −0.65 −0.52
ΔRhinitis subscore −0.51 −0.52 −0.53
ΔAsthma subscore −0.55‡ −0.60 −0.49‡
The correlations between the measures of similar domains are shown in bold.
All correlations were statistically significant with p < 0.001, except * p < 0.01, # p < 0
coefficients: 1) 0.6–0.8 with ACQ5 and with the symptoms VAS; 2) 0.4–0.6 with thepaired T-test to assess the within-patient change in the
CARAT10 score. Moreover, the Guyatt’s responsiveness
index (GRI) was calculated as [17,18]:
GRI
mean change of CARAT 10 in the unstable group
SD of change CARAT 10 in the stable group
:
The longitudinal validity was assessed by Spearman’s
correlation coefficients calculated between the variation
of the CARAT10 score and the variation of the other
measures.
For hypotheses testing, a priori predictions for the cor-
relation coefficients were, based on previous studies as
follows: (i) 0.6–0.8 with ACQ5; (ii) 0.6–0.8 with the
symptoms VAS; (iii) 0.4–0.6 with the physician’s assess-
ment [3,10].
Results
We included 62 patients; one patient did not attend the
2nd visit. Seven patients in the first visit and 3 in the se-
cond incompletely filled out CARAT10 (frequencies of
unanswered questions in the Additional file 1: Table S1);
51 patients completely filled out the CARAT10 ques-
tionnaire in both visits. Table 1 summarizes the sample’s
characteristics, physician assessment, lung function test
results and scorings for the several questionnaires. Table 2
shows the CARAT10 scores according to the patients’
self-perceived control. Scores and subscores of CARAT10
in both visits, in patients with controlled and uncontrolled
rhinitis and asthma, are presented in the Additional file 1:
Table S2.
Seventeen patients (28%) were classified as having
clinically stable asthma and rhinitis. The unstable groupof CARAT10 with the variation of external measures of
S Physician assessment




.05 and § p = 0.09. ‡ did not meet the a priori predictions for the correlation
physician’s assessment.
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rhinitis, 9 only with unstable asthma and 5 only with uns-
table rhinitis.
The plots of CARAT10 scores according to the guide-
lines’ classifications of rhinitis severity and asthma con-
trol are shown in Figure 1.
Properties of CARAT10
Regarding internal consistency, the Cronbach’s α was 0.84
for CARAT10, 0.76 for the rhinitis subscore and 0.80 for theFigure 2 Receiver operating characteristic curves and diagnostic test
and Nasal VAS, (B), GINA and ARIA criteria and (C) ACQ, GINA, Nasal Vasthma subscore. As for the test-retest reliability, an ICC of
0.82 was found in the stable group. Regarding concurrent
validity, all the correlation coefficients between CARAT10/
CARAT factors and 1) control assessment instruments or
2) physician’s assessment met the a priori predictions and
were statistically significant with p < 0.001 (Table 3).
Concerning responsiveness, we observed a significant
within-patient change of CARAT10 scoring in clinically
unstable patients (95% confidence interval [-5.08; -1.31],
p = 0.002). The Guyatt’s responsiveness index was 1.54.properties of CARAT10’ with composite score of (A) ACQ score
AS and ARIA.
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tions between visits ranged from 0.49 to 0.65 for ACQ5 and
the symptoms VAS, while for the physician assessment of
control the coefficients ranged from 0.31 to 0.41. Several cor-
relation coefficients of external measures and CARAT sub-
scores were lower than the a priori predictions, but only one
was below 0.4 [10]. These results are summarized in Table 4.
Receiver operating characteristic (ROC) curves were
plotted, comparing CARAT10’ scores (Figure 2) andFigure 3 Receiver operating characteristic curves and diagnostic test
GINE criteria, and (C) a composite score of GINA and ACQ; and CARAT
symptoms VAS and (F) a composite score of ARIA and the symptomssubscores (Figure 3) with asthma and rhinitis assessment
tools. The AUC for CARAT were between 0.941 and
0.948 for CARAT (Figure 2). Higher AUC were observed
for the asthma factor (0.926-0.942) than for the rhinitis
factor (0.682-0.893) (Figure 3).
Discussion
The longitudinal assessment of the Control of Allergic
Rhinitis and Asthma Test (CARAT10) showed that itproperties of CARAT10’ asthma factor with (A) ACQ score, (B)
10’ rhinitis factor with (D) ARIA classification, (E) the nasal
VAS.
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time.
This is the third phase of a project that aimed to de-
velop and validate a tool to simultaneously assess the con-
trol of rhinitis and asthma. We have previously shown
that CARAT10 has good internal consistency and internal
validity, supporting the concept of a single questionnaire
assessing allergic rhinitis and asthma simultaneously, and
showing it may be used to compare groups [11]. We had
observed good correlations between CARAT10 and
ACQ5, symptoms VAS and the physician’s assessment of
control, similar to that of other widely used control ques-
tionnaires for asthma. The new data confirmed our pre-
vious results. As for test-retest reliability, the ICC for
CARAT10 scores between visits in stable patients was
0.82, better than the ICC previously reported for Asthma
Control Test (ACT) (0.77) [19]. Also, the Guyatt’s respon-
siveness index observed is somewhat higher than that of
ACQ7 (1.35) [3]. Regarding longitudinal validity, like
ACT, CARAT10 correlates better with changes in ACQ
than with the physician’s assessment; the correlation coef-
ficient of CARAT10 with symptoms VAS was similar to
the previously reported correlation of ACQ7 with asthma
symptoms [3,19]. The correlation coefficient for changes
between visits of CARAT10 with the all symptoms VAS
met the a priori predictions (Table 4). The correlation
coefficients of CARAT10 subscores with external mea-
sures of rhinitis and asthma status were lower than pre-
dicted. These subscores were defined using standard
procedures of exploratory factor analysis in a previous
study [11]. However, questions on waking up at night or
increasing medication may be related to asthma and/or
rhinitis in different patients. Therefore, a reassessment of
CARAT10 structure in different populations seems to be
necessary.
In this multicenter longitudinal study, it was necessary
to categorize patients as clinically stable or unstable bet-
ween visits. The criterion was the physician’s rating of
control variation between visits, since there is no gold
standard for the measurement of control of allergic rhi-
nitis and asthma. The intrinsic insufficiencies of physician
rating [20] may undermine the results observed. However,
the direction of this bias worsens the questionnaire’s pro-
perties. Therefore, the estimates for the evaluative and dis-
criminative properties of CARAT10 are conservatively
reported.
CARAT10 has been thoroughly studied in cross-sec-
tional and prospective studies and now meets almost all
requirements of COSMIN - COnsensus-based Standards
for the selection of health Measurement Instruments [21].
Further studies with larger datasets are needed to firmly
establish the cut values for the CARAT10 global score and
the rhinitis and asthma subscores [22]. The existing data
seems to suggest that a CARAT10 score over 24 identifiescontrolled patients, with a rhinitis subscore over 8 and an
asthma subscore equal or greater than 16.
The availability of CARAT10 for clinical practice in
multiple countries requires cross-cultural validation in
other languages. A website to support an adequate process
of translation was developed (http://www.caratnetwork.org)
and researchers are invited to participate. Cross-cultural
adaptation of CARAT has started in over 10 different coun-
tries [23]. It was organized in 3 phases, following the Global
Allergy and Asthma European Network (GA2LEN) net-
work recommendations [24]: forward translation, backward
translation and patient testing; clinical validation studies for
these languages should follow.
In summary, this study showed that CARAT10 has
adequate test-retest reliability, responsiveness and lon-
gitudinal validity while confirming its high internal con-
sistency and concurrent validity. Therefore, CARAT10 can
be used both in clinical studies and in clinical practice, to
compare groups and to evaluate individual patients over
time.
Additional file
Additional file 1: Table S1. Frequencies of unanswered questions of
CARAT 10 in each visit. Table S2 - Scores and subscores of CARAT 10 in
both visits in patients with controlled and uncontrolled rhinitis and
asthma. Figures S1 - Study design - data collection and properties
evaluation.
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